Alkem Laboratories Ltd has announced an interim dividend of ₹43 per equity share of face value ₹2 per share for financial year 2025-2026. According to the company's February 13 exchange filing, the dividend was declared pursuant to Regulation 43 read with Regulation 30 of SEBI LODR Regulations. The multinational pharma company, which was incorporated on August 8, 1973, in Patna, Bihar, and later established its headquarters in Mumbai, made this announcement alongside the release of its Q3 quarterly results for FY26.
The record date for the interim dividend has been fixed as February 20, 2026, as announced in the company's regulatory filing. The payment of interim dividend will commence on and from March 6, 2026. As reported by ET Now, this record date identifies shareholders eligible for the dividend payment, with the company following proper SEBI regulations for corporate actions.
According to the company's Q3 results announcement, consolidated net profit rose 1.9% to ₹653.03 crore in the third quarter ended December 31, 2025, compared to ₹640.79 crore in the corresponding quarter of the previous fiscal year. Consolidated revenue from operations increased to ₹3,736.82 crore from ₹3,374.28 crore in the year-ago period. However, total expenses rose to ₹3,045.93 crore compared to ₹2,736.2 crore in the same period last fiscal.
As reported by ET Now, Alkem Laboratories has signed a binding term sheet to acquire a majority stake in Swiss medical devices firm Occlutech Holding AG at a total equity value of 180.7 million euros. The company also recorded an exceptional item outgo of ₹52.79 crore during the third quarter due to the impact of new labour codes. The acquisition represents the company's strategic expansion into the medical devices sector.
